ZEALAND PHARMA/S (ZEAL) Upgraded to “Hold” by ValuEngine

ZEALAND PHARMA/S (NASDAQ:ZEAL) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

Several other equities research analysts have also recently weighed in on ZEAL. Zacks Investment Research upgraded ZEALAND PHARMA/S from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Tuesday, January 1st. TheStreet upgraded ZEALAND PHARMA/S from a “d+” rating to a “c-” rating in a research note on Tuesday, January 22nd. Needham & Company LLC restated a “buy” rating and set a $29.00 target price on shares of ZEALAND PHARMA/S in a research note on Thursday, March 7th. Finally, Goldman Sachs Group cut ZEALAND PHARMA/S from a “buy” rating to a “neutral” rating in a research note on Monday, December 17th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $24.00.

ZEAL stock traded down $0.23 during trading on Friday, hitting $15.37. 434 shares of the company’s stock were exchanged, compared to its average volume of 4,686. The stock has a market cap of $475.76 million, a price-to-earnings ratio of -10.39 and a beta of 2.21. ZEALAND PHARMA/S has a 52-week low of $11.51 and a 52-week high of $18.91.

A hedge fund recently bought a new stake in ZEALAND PHARMA/S stock. OLD Mission Capital LLC acquired a new stake in ZEALAND PHARMA/S (NASDAQ:ZEAL) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 17,466 shares of the company’s stock, valued at approximately $203,000. OLD Mission Capital LLC owned about 0.06% of ZEALAND PHARMA/S at the end of the most recent quarter. 9.24% of the stock is currently owned by institutional investors and hedge funds.

About ZEALAND PHARMA/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.

Recommended Story: What is the Coverage Ratio?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.